Full history for every metric is available with a Kvantra account
Liminal BioSciences Inc. (LMNL)
Key financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 39 | 47 | 5 | 3 | 1 | 0 | 0 |
| Operating profit | CAD m | -33 | -34 | |||||
| Net profit | CAD m | -110 | -195 | -234 | -122 | -45 | -29 | - |
| EPS reported | CAD | -9.32 | - | |||||
| Operating cashflow per share | CAD | -376.1 | -376.1 | |||||
| Capex per share | CAD | 0.22 | 0.22 | |||||
| FCF per share | CAD | -376.3 | -376.3 | |||||
| Free cash flow | CAD m | -32 | -36 | |||||
| Net debt | CAD m | -36 | -19 | |||||
| Book value equity | CAD m | 36 | 21 | |||||
| Book value per share | CAD | 11.66 | 6.92 | |||||
| Number of shares | m | 3.1 | 3.1 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.01 | 1.83 | |||||
| P/S LTM | x | 0.93 | 79.99 | |||||
| P/FCF LTM | x | -0.01 | -1.09 | |||||
| EV/EBITDA LTM | x | 1.11 | -0.50 | |||||
| EV/Sales LTM | x | -87.99 | 40.74 | |||||
| Earnings Yield LTM | % | -7766.4% | -2821.5% | |||||
| FCF Yield | % | -8551.4% | -91.74% | |||||
| Quality | ||||||||
| ROE | % | -79.86% | -73.35% | |||||
| ROIC | % | -78.82% | -78.82% | |||||
| Operating margin | % | -8223.2% | -8223.2% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -7939.9% | -7939.9% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -37.64% | -12.92% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -21.41 | -29.91 | |||||
| Net Debt/EBITDA | x | 1.12 | 1.12 | |||||
| EBIT/Net interest | x | -30.59 | -30.59 | |||||
| Net debt/market cap | % | -9576.9% | -49.08% | |||||
| Net debt/Equity | x | -0.98 | -0.90 | |||||
| Gross debt/equity | x | 0.04 | 0.06 | |||||
Company overview
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Liminal BioSciences Inc. (LMNL)
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free